hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== I == idiopathic – idiopathic thrombocytopenia purpura – IHS – immune complex – immune deficiency/immunodeficiency – immune response – immune system – immune thrombocytopenic purpura – immunity – immunization – immunocompetent – immunocompromised – immunodeficiency – immunogen – immunogenicity – immunoglobulin (Ig) – immunoglobulin A (IgA) – immunoglobulin D (IGD) – immunoglobulin E (IGE) – immunoglobulin G (IGG) – immunoglobulin M (IGM) – immunomodulator – immunostimulant – immunosuppression – immunotherapy – immunotoxin – in vitro – in vivo – incidence – Incubation period – IND – Indian Health Service (IHS) – infection – infectious – informed consent – infusion – inoculation – institutional review board (IRB) – integrase – integrase inhibitors – Interaction – interferon – interleukin-1 (IL-1) – interleukin-2 (IL-2) – interleukin-4 (IL-4) – interleukin-12 (IL-12) – interleukins – International Center for Research on Women – intramuscular (IM) – intravenous – intravenous immunoglobulin (IVIG) – intravitreal – Investigational New Drug (IND) – IRB – ITP – IVIG
Minoxidil was discovered in 1963 and was introduced for treatment of high blood pressure in 1971. In 1971, researchers unexpectedly discovered that minoxidil causes hair growth, resulting in it being repurposed for treatment of hair loss and approved in topical form for this use in 1988. Topical minoxidil became available over-the-counter in 1996. Low-dose oral minoxidil (LDOM) emerged for treatment of hair loss in 2015 and dramatically increased in popularity starting in 2022. Extended-release oral minoxidil and sublingual minoxidil were developed in the 2020s for hair loss and are in late-stage trials. Aside from its use in humans, minoxidil is extremely toxic to cats and dogs even in small amounts.
The Mediterranean seeps appear to represent a rich habitat characterized by megafauna species richness (e.g., gastropods) or the exceptional size of some species such as sponges (Rhizaxinella pyrifera) and crabs (Chaceon mediterraneus), compared with their background counterparts. This contrasts with the low macro- and mega-faunal abundance and diversity of the deep eastern Mediterranean. Seep communities in the Mediterranean that include endemic chemosynthetic species and associated fauna differ from the other known seep communities in the world at the species level but also by the absence of the large-size bivalve genera Calyptogena or Bathymodiolus. The isolation of the Mediterranean seeps from the Atlantic Ocean after the Messinian crisis led to the development of unique communities, which are likely to differ in composition and structure from those in the Atlantic Ocean. Further expeditions involved quantitative sampling of habitats in different areas, from the Mediterranean Ridge to the eastern Nile deep-sea fan. Cold seeps discovered in the Sea of Marmara in 2008 have also revealed chemosynthesis-based communities that showed a considerable similarity to the symbiont-bearing fauna of eastern Mediterranean cold seeps.
== Brands == Folgers established brand colors, included on their logo, were traditionally a moderately dark red background with white lettering. The white or grey lettering is still used, with a green background signifying decaf and a black background signifying their Noir dark roast. Folgers products available in the United States include:
=== EC 2.3.1: Transferring groups other than amino-acyl groups === EC 2.3.1.1: amino-acid N-acetyltransferase EC 2.3.1.2: imidazole N-acetyltransferase EC 2.3.1.3: glucosamine N-acetyltransferase EC 2.3.1.4: glucosamine-phosphate N-acetyltransferase EC 2.3.1.5: arylamine N-acetyltransferase EC 2.3.1.6: choline O-acetyltransferase EC 2.3.1.7: carnitine O-acetyltransferase EC 2.3.1.8: phosphate acetyltransferase EC 2.3.1.9: acetyl-CoA C-acetyltransferase EC 2.3.1.10: hydrogen-sulfide S-acetyltransferase EC 2.3.1.11: thioethanolamine S-acetyltransferase EC 2.3.1.12: dihydrolipoyllysine-residue acetyltransferase EC 2.3.1.13: glycine N-acyltransferase EC 2.3.1.14: glutamine N-phenylacetyltransferase EC 2.3.1.15: glycerol-3-phosphate O-acyltransferase EC 2.3.1.16: acetyl-CoA C-acyltransferase EC 2.3.1.17: aspartate N-acetyltransferase EC 2.3.1.18: galactoside O-acetyltransferase EC 2.3.1.19: phosphate butyryltransferase EC 2.3.1.20: diacylglycerol O-acyltransferase EC 2.3.1.21: carnitine O-palmitoyltransferase EC 2.3.1.22: 2-acylglycerol O-acyltransferase EC 2.3.1.23: 1-acylglycerophosphocholine O-acyltransferase EC 2.3.1.24: sphingosine N-acyltransferase EC 2.3.1.25: plasmalogen synthase EC 2.3.1.26: sterol O-acyltransferase EC 2.3.1.27: cortisol O-acetyltransferase EC 2.3.1.28: chloramphenicol O-acetyltransferase EC 2.3.1.29: glycine C-acetyltransferase EC 2.3.1.30: serine O-acetyltransferase EC 2.3.1.31: homoserine O-acetyltransferase EC 2.3.1.32: lysine N-acetyltransferase EC 2.3.1.33: histidine N-acetyltransferase EC 2.3.1.34: D-tryptophan N-acetyltransferase EC 2.3.1.35: glutamate N-acetyltransferase EC 2.3.1.36: D-amino-acid N-acetyltransferase EC 2.3.1.37: 5-aminolevulinate synthase EC 2.3.1.38: [acyl-carrier-protein] S-acetyltransferase EC 2.3.1.39: [acyl-carrier-protein] S-malonyltransferase EC 2.3.1.40: acyl-[acyl-carrier-protein]—phospholipid O-acyltransferase EC 2.3.1.41: β-ketoacyl-[acyl-carrier-protein] synthase I EC 2.3.1.42: glycerone-phosphate O-acyltransferase EC 2.3.1.43: phosphatidylcholine—sterol O-acyltransferase EC 2.3.1.44: N-acetylneuraminate 4-O-acetyltransferase EC 2.3.1.45: N-acetylneuraminate 7-O(or 9-O)-acetyltransferase EC 2.3.1.46: homoserine O-succinyltransferase EC 2.3.1.47: 8-amino-7-oxononanoate synthase EC 2.3.1.48: histone acetyltransferase EC 2.3.1.49: deacetyl-(citrate-(pro-3S)-lyase) S-acetyltransferase EC 2.3.1.50: serine C-palmitoyltransferase EC 2.3.1.51: 1-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.52: 2-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.53: phenylalanine N-acetyltransferase EC 2.3.1.54: formate C-acetyltransferase EC 2.3.1.55: identical to EC 2.3.1.82 EC 2.3.1.56: aromatic-hydroxylamine O-acetyltransferase EC 2.3.1.57: diamine N-acetyltransferase EC 2.3.1.58: 2,3-diaminopropionate N-oxalyltransferase EC 2.3.1.59: gentamicin 2′-N-acetyltransferase EC 2.3.1.60: gentamicin 3′-N-acetyltransferase EC 2.3.1.61: dihydrolipoyllysine-residue succinyltransferase EC 2.3.1.62: 2-acylglycerophosphocholine O-acyltransferase EC 2.3.1.63: 1-alkylglycerophosphocholine O-acyltransferase EC 2.3.1.64: agmatine N4-coumaroyltransferase EC 2.3.1.65: bile acid-CoA:amino acid N-acyltransferase EC 2.3.1.66: leucine N-acetyltransferase EC 2.3.1.67: 1-alkylglycerophosphocholine O-acetyltransferase EC 2.3.1.68: glutamine N-acyltransferase EC 2.3.1.69: monoterpenol O-acetyltransferase EC 2.3.1.70: deleted EC 2.3.1.71: glycine N-benzoyltransferase EC 2.3.1.72: indoleacetylglucose—inositol O-acyltransferase EC 2.3.1.73: diacylglycerol—sterol O-acyltransferase EC 2.3.1.74: chalcone synthase EC 2.3.1.75: long-chain-alcohol O-fatty-acyltransferase EC 2.3.1.76: retinol O-fatty-acyltransferase EC 2.3.1.77: triacylglycerol—sterol O-acyltransferase EC 2.3.1.78: heparan-α-glucosaminide N-acetyltransferase EC 2.3.1.79: maltose O-acetyltransferase EC 2.3.1.80: cysteine-S-conjugate N-acetyltransferase EC 2.3.1.81: aminoglycoside 3-N-acetyltransferase EC 2.3.1.82: aminoglycoside 6′-N-acetyltransferase EC 2.3.1.83: phosphatidylcholine—dolichol O-acyltransferase EC 2.3.1.84: alcohol O-acetyltransferase EC 2.3.1.85: fatty-acid synthase system EC 2.3.1.86: fatty-acyl-CoA synthase system EC 2.3.1.87: aralkylamine N-acetyltransferase EC 2.3.1.88: Now covered by EC 2.3.1.254, EC 2.3.1.255, EC 2.3.1.256, EC 2.3.1.257, EC 2.3.1.258 and EC 2.3.1.259 EC 2.3.1.89: tetrahydrodipicolinate N-acetyltransferase EC 2.3.1.90: β-glucogallin O-galloyltransferase EC 2.3.1.91: sinapoylglucose—choline O-sinapoyltransferase EC 2.3.1.92: sinapoylglucose—malate O-sinapoyltransferase EC 2.3.1.93: 13-hydroxylupinine O-tigloyltransferase EC 2.3.1.94: 6-deoxyerythronolide-B synthase EC 2.3.1.95: trihydroxystilbene synthase EC 2.3.1.96: glycoprotein N-palmitoyltransferase EC 2.3.1.97: glycylpeptide N-tetradecanoyltransferase EC 2.3.1.98: chlorogenate—glucarate O-hydroxycinnamoyltransferase EC 2.3.1.99: quinate O-hydroxycinnamoyltransferase EC 2.3.1.100: [myelin-proteolipid] O-palmitoyltransferase EC 2.3.1.101: formylmethanofuran—tetrahydromethanopterin N-formyltransferase EC 2.3.1.102: N6-hydroxylysine O-acetyltransferase EC 2.3.1.103: sinapoylglucose—sinapoylglucose O-sinapoyltransferase EC 2.3.1.104: The activity is covered by EC 2.3.1.25 EC 2.3.1.105: alkylglycerophosphate 2-O-acetyltransferase EC 2.3.1.106: tartronate O-hydroxycinnamoyltransferase EC 2.3.1.107: deacetylvindoline O-acetyltransferase EC 2.3.1.108: α-tubulin N-acetyltransferase EC 2.3.1.109: arginine N-succinyltransferase EC 2.3.1.110: tyramine N-feruloyltransferase EC 2.3.1.111: mycocerosate synthase EC 2.3.1.112: D-tryptophan N-malonyltransferase EC 2.3.1.113: anthranilate N-malonyltransferase EC 2.3.1.114: 3,4-dichloroaniline N-malonyltransferase EC 2.3.1.115: isoflavone-7-O-β-glucoside 6′′-O-malonyltransferase EC 2.3.1.116: flavonol-3-O-β-glucoside O-malonyltransferase EC 2.3.1.117: 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase EC 2.3.1.118: N-hydroxyarylamine O-acetyltransferase EC 2.3.1.119: Now covered by EC 2.3.1.199, EC 1.1.1.330, EC 4.2.1.134 and EC 1.3.1.93 EC 2.3.1.120: The reaction is due to EC 2.3.1.74 EC 2.3.1.121: 1-alkenylglycerophosphoethanolamine O-acyltransferase EC 2.3.1.122: trehalose O-mycolyltransferase EC 2.3.1.123: dolichol O-acyltransferase EC 2.3.1.124: Already listed as EC 2.3.1.20 EC 2.3.1.125: 1-alkyl-2-acetylglycerol O-acyltransferase EC 2.3.1.126: isocitrate O-dihydroxycinnamoyltransferase EC 2.3.1.127: ornithine N-benzoyltransferase EC 2.3.1.128: now classified as EC 2.3.1.266 and EC 2.3.1.267 EC 2.3.1.129: acyl-[acyl-carrier-protein]—UDP-N-acetylglucosamine O-acyltransferase EC 2.3.1.130: galactarate O-hydroxycinnamoyltransferase EC 2.3.1.131: glucarate O-hydroxycinnamoyltransferase EC 2.3.1.132: glucarolactone O-hydroxycinnamoyltransferase EC 2.3.1.133: shikimate O-hydroxycinnamoyltransferase EC 2.3.1.134: galactolipid O-acyltransferase EC 2.3.1.135: phosphatidylcholine—retinol O-acyltransferase EC 2.3.1.136: polysialic-acid O-acetyltransferase EC 2.3.1.137: carnitine O-octanoyltransferase EC 2.3.1.138: putrescine N-hydroxycinnamoyltransferase EC 2.3.1.139: ecdysone O-acyltransferase EC 2.3.1.140: rosmarinate synthase EC 2.3.1.141: galactosylacylglycerol O-acyltransferase EC 2.3.1.142: glycoprotein O-fatty-acyltransferase EC 2.3.1.143: β-glucogallin—tetrakisgalloylglucose O-galloyltransferase EC 2.3.1.144: anthranilate N-benzoyltransferase EC 2.3.1.145: piperidine N-piperoyltransferase EC 2.3.1.146: pinosylvin synthase EC 2.3.1.147: glycerophospholipid arachidonoyl-transferase (CoA-independent) EC 2.3.1.148: glycerophospholipid acyltransferase (CoA-dependent) EC 2.3.1.149: platelet-activating factor acetyltransferase EC 2.3.1.150: salutaridinol 7-O-acetyltransferase EC 2.3.1.151: 2,3′,4,6-tetrahydroxybenzophenone synthase EC 2.3.1.152: alcohol O-cinnamoyltransferase EC 2.3.1.153: anthocyanin 5-(6′′′-hydroxycinnamoyltransferase) EC 2.3.1.154: Now EC 2.3.1.176 EC 2.3.1.155: acetyl-CoA C-myristoyltransferase EC 2.3.1.156: phloroisovalerophenone synthase EC 2.3.1.157: glucosamine-1-phosphate N-acetyltransferase EC 2.3.1.158: phospholipid:diacylglycerol acyltransferase EC 2.3.1.159: acridone synthase EC 2.3.1.160: vinorine synthase EC 2.3.1.161: lovastatin nonaketide synthase EC 2.3.1.162: taxadien-5α-ol O-acetyltransferase EC 2.3.1.163: 10-hydroxytaxane O-acetyltransferase EC 2.3.1.164: isopenicillin-N N-acyltransferase EC 2.3.1.165: 6-methylsalicylic acid synthase EC 2.3.1.166: 2α-hydroxytaxane 2-O-benzoyltransferase EC 2.3.1.167: 10-deacetylbaccatin III 10-O-acetyltransferase EC 2.3.1.168: dihydrolipoyllysine-residue (2-methylpropanoyl)transferase EC 2.3.1.169: CO-methylating acetyl-CoA synthase EC 2.3.1.170: 6′-deoxychalcone synthase EC 2.3.1.171: anthocyanin 6′′-O-malonyltransferase EC 2.3.1.172: anthocyanin 5-O-glucoside 6′′′-O-malonyltransferase EC 2.3.1.173: flavonol-3-O-triglucoside O-coumaroyltransferase EC 2.3.1.174: 3-oxoadipyl-CoA thiolase EC 2.3.1.175: deacetylcephalosporin-C acetyltransferase EC 2.3.1.176: propanoyl-CoA C-acyltransferase EC 2.3.1.177: 3,5-dihydroxybiphenyl synthase EC 2.3.1.178: diaminobutyrate acetyltransferase EC 2.3.1.179: β-ketoacyl-[acyl-carrier-protein] synthase II EC 2.3.1.180: β-ketoacyl-[acyl-carrier-protein] synthase III EC 2.3.1.181: lipoyl(octanoyl) transferase EC 2.3.1.182: Now covered by EC 2.3.3.21 EC 2.3.1.183: phosphinothricin acetyltransferase EC 2.3.1.184: acyl-homoserine-lactone synthase EC 2.3.1.185: tropine acyltransferase EC 2.3.1.186: pseudotropine acyltransferase EC 2.3.1.187: acetyl-S-ACP:malonate ACP transferase EC 2.3.1.188: ω-hydroxypalmitate O-feruloyl transferase EC 2.3.1.189: mycothiol synthase EC 2.3.1.190: acetoin dehydrogenase EC 2.3.1.191: UDP-3-O-(3-hydroxyacyl)glucosamine N-acyltransferase EC 2.3.1.192: glycine N-phenylacetyltransferase EC 2.3.1.193: tRNAMetcytidine acetyltransferase EC 2.3.1.194: acetoacetyl-CoA synthase EC 2.3.1.195: (Z)-3-hexen-1-ol acetyltransferase EC 2.3.1.196: benzyl alcohol O-benzoyltransferase EC 2.3.1.197: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose 3-N-acetyltransferase EC 2.3.1.198: glycerol-3-phosphate 2-O-acyltransferase EC 2.3.1.199: very-long-chain 3-oxoacyl-CoA synthase EC 2.3.1.200: lipoyl amidotransferase EC 2.3.1.201: UDP-2-acetamido-3-amino-2,3-dideoxy-glucuronate N-acetyltransferase EC 2.3.1.202: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine N-acetyltransferase EC 2.3.1.203: UDP-N-acetylbacillosamine N-acetyltransferase EC 2.3.1.204: octanoyl-[GcvH]:protein N-octanoyltransferase EC 2.3.1.205: fumigaclavine B O-acetyltransferase EC 2.3.1.206: 3,5,7-trioxododecanoyl-CoA synthase EC 2.3.1.207: β-ketodecanoyl-[acyl-carrier-protein] synthase EC 2.3.1.208: 4-hydroxycoumarin synthase EC 2.3.1.209: dTDP-4-amino-4,6-dideoxy-D-glucose acyltransferase EC 2.3.1.210: dTDP-4-amino-4,6-dideoxy-D-galactose acyltransferase EC 2.3.1.211: bisdemethoxycurcumin synthase EC 2.3.1.212: benzalacetone synthase EC 2.3.1.213: cyanidin 3-O-(6-O-glucosyl-2-O-xylosylgalactoside) 6′′′-O-hydroxycinnamoyltransferase EC 2.3.1.214: pelargonidin 3-O-(6-caffeoylglucoside) 5-O-(6-O-malonylglucoside) 4′′′-malonyltransferase EC 2.3.1.215: anthocyanin 3-O-glucoside 6-O-hydroxycinnamoyltransferase EC 2.3.1.216: 5,7-dihydroxy-2-methylchromone synthase EC 2.3.1.217: curcumin synthase EC 2.3.1.218: phenylpropanoylacetyl-CoA synthase EC 2.3.1.219: demethoxycurcumin synthase EC 2.3.1.220: 2,4,6-trihydroxybenzophenone synthase EC 2.3.1.221: noranthrone synthase EC 2.3.1.222: phosphate propanoyltransferase EC 2.3.1.223: 3-oxo-5,6-didehydrosuberyl-CoA thiolase EC 2.3.1.224: acetyl-CoA-benzylalcohol acetyltransferase EC 2.3.1.225: protein S-acyltransferase EC 2.3.1.226: carboxymethylproline synthase EC 2.3.1.227: GDP-perosamine N-acetyltransferase EC 2.3.1.228: isovaleryl-homoserine lactone synthase EC 2.3.1.229: 4-coumaroyl-homoserine lactone synthase EC 2.3.1.230: 2-heptyl-4(1H)-quinolone synthase EC 2.3.1.231: tRNAPhe {7-[3-amino-3-(methoxycarbonyl)propyl]wyosine37 -N}-methoxycarbonyltransferase EC 2.3.1.232: methanol O-anthraniloyltransferase EC 2.3.1.233: 1,3,6,8-tetrahydroxynaphthalene synthase EC 2.3.1.234: N6-L-threonylcarbamoyladenine synthase EC 2.3.1.235: tetracenomycin F2 synthase EC 2.3.1.236: 5-methylnaphthoic acid synthase EC 2.3.1.237: neocarzinostatin naphthoate synthase EC 2.3.1.238: monacolin J acid methylbutanoate transferase EC 2.3.1.239: 10-deoxymethynolide synthase EC 2.3.1.240: narbonolide synthase EC 2.3.1.241: Kdo2-lipid IVA lauroyltransferase EC 2.3.1.242: Kdo2-lipid IVA palmitoleoyltransferase EC 2.3.1.243: lauroyl-Kdo2-lipid IVA myristoyltransferase EC 2.3.1.244: 2-methylbutanoate polyketide synthase EC 2.3.1.245: 3-hydroxy-5-phosphooxypentane-2,4-dione thiolase EC 2.3.1.246: 3,5-dihydroxyphenylacetyl-CoA synthase EC 2.3.1.247: 3-keto-5-aminohexanoate cleavage enzyme EC 2.3.1.248: spermidine disinapoyl transferase EC 2.3.1.249: spermidine dicoumaroyl transferase EC 2.3.1.250: [Wnt protein] O-palmitoleoyl transferase EC 2.3.1.251: lipid IVA palmitoyltransferase EC 2.3.1.252: mycolipanoate synthase EC 2.3.1.253: phloroglucinol synthase EC 2.3.1.254: N-terminal methionine Nα-acetyltransferase NatB EC 2.3.1.255: N-terminal amino-acid Nα-acetyltransferase NatA EC 2.3.1.256: N-terminal methionine Nα-acetyltransferase NatC EC 2.3.1.257: N-terminal L-serine Nα-acetyltransferase NatD EC 2.3.1.258: N-terminal methionine Nα-acetyltransferase NatE EC 2.3.1.259: N-terminal methionine Nα-acetyltransferase NatF EC 2.3.1.260: tetracycline polyketide synthase EC 2.3.1.261: (4-hydroxyphenyl)alkanoate synthase EC 2.3.1.262: anthraniloyl-CoA anthraniloyltransferase EC 2.3.1.263: 2-amino-4-oxopentanoate thiolase EC 2.3.1.264: β-lysine N6-acetyltransferase EC 2.3.1.265: phosphatidylinositol dimannoside acyltransferase EC 2.3.1.266: [ribosomal protein S18]-alanine N-acetyltransferase EC 2.3.1.267: [ribosomal protein S5]-alanine N-acetyltransferase EC 2.3.1.268: ethanol O-acetyltransferase EC 2.3.1.269: apolipoprotein N-acyltransferase EC 2.3.1.270: lyso-ornithine lipid O-acyltransferase EC 2.3.1.271: L-glutamate-5-semialdehyde N-acetyltransferase EC 2.3.1.272: 2-acetylphloroglucinol acetyltransferase EC 2.3.1.273: diglucosylglycerate octanoyltransferase EC 2.3.1.274: phosphate acyltransferase EC 2.3.1.275: acyl phosphate:glycerol-3-phosphate acyltransferase EC 2.3.1.276: galactosamine-1-phosphate N-acetyltransferase EC 2.3.1.277: 2-oxo-3-(phosphooxy)propyl 3-oxoalkanoate synthase EC 2.3.1.278: mycolipenoyl-CoA—2-(long-chain-fatty acyl)-trehalose mycolipenoyltransferase EC 2.3.1.279: long-chain-acyl-CoA—trehalose acyltransferase EC 2.3.1.280: (aminoalkyl)phosphonate N-acetyltransferase EC 2.3.1.281: 5-hydroxydodecatetraenal polyketide synthase EC 2.3.1.282: phenolphthiocerol/phthiocerol/phthiodiolone dimycocerosyl transferase EC 2.3.1.283: 2′-acyl-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.284: 3′-(hydroxy)phthioceranyl-2′-palmitoyl(stearoyl)-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.285: (13S,14R)-1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase EC 2.3.1.286: protein acetyllysine N-acetyltransferase EC 2.3.1.287: phthioceranic/hydroxyphthioceranic acid synthase EC 2.3.1.288: 2-O-sulfo trehalose long-chain-acyltransferase EC 2.3.1.289: aureothin polyketide synthase system EC 2.3.1.290: spectinabilin polyketide synthase system EC 2.3.1.291: sphingoid base N-palmitoyltransferase EC 2.3.1.292: (phenol)carboxyphthiodiolenone synthase EC 2.3.1.293: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase I EC 2.3.1.294: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase II EC 2.3.1.295: mycoketide-CoA synthase EC 2.3.1.296: ω-hydroxyceramide transacylase EC 2.3.1.297: very-long-chain ceramide synthase EC 2.3.1.298: ultra-long-chain ceramide synthase EC 2.3.1.299: sphingoid base N-stearoyltransferase EC 2.3.1.300: branched-chain β-ketoacyl-[acyl-carrier-protein] synthase EC 2.3.1.301: mycobacterial β-ketoacyl-[acyl carrier protein] synthase III EC 2.3.1.302: hydroxycinnamoyl-CoA:5-hydroxyanthranilate N-hydroxycinnamoyltransferase EC 2.3.1.303: α-L-Rha-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und 2IV-O-acetyltransferase EC 2.3.1.304: poly[(S)-3-hydroxyalkanoate] polymerase
Sources: en.wikipedia.org
=== In LTP === When alpha-CaMKII is knocked out in mice, LTP is reduced by 50%. This can be explained by the fact that beta-CaMKII is responsible for approximately 65% of CaMKII activity. LTP can be completely blocked if CaMKII is modified so that it cannot remain active. After LTP induction, CaMKII moves to the postsynaptic density (PSD). However, if the stimulation does not induce LTP, the translocation is quickly reversible. Binding to the PSD changes CaMKII so that it is less likely to become dephosphorylated. CaMKII transforms from a substrate for Protein Phosphatase 2A (PP2A), which is responsible for dephosphorylating CaMKII, to that of Protein Phosphatase 1. Strack, S. (1997) demonstrated this phenomenon by chemically stimulating hippocampal slices. This experiment illustrates that CaMKII contributes to the enhancement of synaptic strength. Sanhueza et al. found that persistent activation of CaMKII is necessary for the maintenance of LTP. She induced LTP in hippocampal slices and experimentally applied an antagonist (CaMKIINtide) to prevent CaMKII from remaining active. The slices that were applied with CaMKIINtide showed a decrease in Normalized EPSP slope after the drug infusion, meaning that the induced LTP reversed itself. The Normalized EPSP slope remained constant in the control; CaMKII continues to be involved in the LTP maintenance process even after LTP establishment. CaMKII is activated by calcium/calmodulin, but it is maintained by autophosphorylation. CaMKII is activated by the NMDA-receptor-mediated Calcium elevation that occurs during LTP induction.
He beat Andrey Rublev for the 17th title of his career and the fourth of the season, in 59 minutes, the shortest match in the tournament history. At the US Open, Zverev sought to claim his first major title following his run to the final the previous year. He reached the semifinals following wins over Jack Sock and Lloyd Harris. There, he lost to Novak Djokovic in five sets despite taking the first set, ending his career-high 16-match win streak stretching back to the Olympics. Zverev was seeded 3rd at the 2021 BNP Paribas Open, where he reached the quarterfinals. On the way, he defeated Jenson Brooksby, Andy Murray and Gaël Monfils. He lost to Taylor Fritz, despite having two match points. At the Erste Bank Open in Vienna, seeded second, he defeated Filip Krajinović and Alex de Minaur to reach the quarterfinals. The victory over De Minaur gave Zverev his 300th ATP tour match win. He then beat Félix Auger-Aliassime and Carlos Alcaraz to reach the final where he won his fifth title of the year and 18th overall, defeating Frances Tiafoe in straight sets. Zverev was the fourth seed at the 2021 Rolex Paris Masters. He received a bye into the second round, where he defeated Dušan Lajović. He defeated next sixteenth seed Grigor Dimitrov in the third round and sixth seed Casper Ruud in the quarterfinals. He lost in the semifinals to second seed Daniil Medvedev in straight sets. As a result of this run he equaled his singles career-high ranking of World No. 3 on 8 November 2021. For a fifth successive season, Zverev qualified for the 2021 ATP Finals in Turin, as the third seed.
Liakhov, a vigorous, able, and reactionary officer firmly committed to upholding absolute monarchies whatever in Russia or Iran, transformed the Persian Cossack Brigade into a mounted para-military police force rather than as a combat force. Liakhov was close to the new Shah, Mohammed Ali, who ascended to the Peacock Throne in January 1907, and it was due to the shah's patronage that Liakhov transformed the Persian Cossack Brigade into the main bulwark of the Iranian state. In June 1908, Liakhov led the Cossack Brigade in bombarding the Majlis (Parliament) while being appointed military governor of Tehran as the shah attempted to do away with the constitution his father had been forced to grant in 1906 Reza Khan, who became the first Iranian to command the Cossack Brigade led the coup d'état in 1921 and in 1925 deposed the Qajars to found a new dynasty. After the outbreak of World War I in August 1914, Cossacks became a key component in the cavalry of the Imperial Russian Army. The mounted Cossacks made up 38 regiments, plus some infantry battalions and 52 horse artillery batteries. Initially, each Russian cavalry division included a regiment of Cossacks in addition to regular units of hussars, lancers, and dragoons. By 1916, the Cossacks' wartime strength had expanded to 160 regiments, plus 176 independent sotnias (squadrons) employed as detached units. The importance of cavalry in the frontlines faded after the opening phase of the war settled into a stalemate.
Glutathione S-transferase Mu 4 is an enzyme that in humans is encoded by the GSTM4 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase that belongs to the mu class. The mu class of enzymes functions in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding the mu class of enzymes are organized in a gene cluster on chromosome 1p13.3 and are known to be highly polymorphic. These genetic variations can change an individual's susceptibility to carcinogens and toxins as well as affect the toxicity and efficacy of certain drugs. Diversification of these genes has occurred in regions encoding substrate-binding domains, as well as in tissue expression patterns, to accommodate an increasing number of foreign compounds. Multiple transcript variants, each encoding a distinct protein isoform, have been identified. In the August 2009 issue of Oncogene journal, researchers at Huntsman Cancer Institute (HCI) at the University of Utah demonstrated that expression levels of GSTM4 could predict response to chemotherapy in patients with Ewing sarcoma. The study found that patients who did not respond to chemotherapy had high levels of GSTM4.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
Sources: en.wikipedia.org
=== Takeshita === The Takeshita geometry consists of a 54.43° electric sector, and short drift length, a second electric sector of the same curvature direction followed by another drift length before a 180° magnetic sector of opposite curvature direction.
Food packaging is a packaging system specifically designed for food and represents one of the most important aspects among the processes involved in the food industry, as it provides protection from chemical, biological and physical alterations. The main goal of food packaging is to provide a practical means of protecting and delivering food goods at a reasonable cost, while meeting the needs and expectations of both consumers and industries. Additionally, current trends like sustainability, environmental impact reduction, and shelf-life extension have gradually become some of the most important aspects in designing a packaging system.
A preservative is a substance or a chemical that is added to products such as food products, beverages, pharmaceutical drugs, paints, biological samples, cosmetics, wood, and many other products to prevent decomposition by microbial growth or by undesirable chemical changes. In general, preservation is implemented in two modes, chemical and physical. Chemical preservation entails adding chemical compounds to the product. Physical preservation entails processes such as refrigeration or drying. Preservative food additives reduce the risk of foodborne infections, decrease microbial spoilage, and preserve fresh attributes and nutritional quality. Some physical techniques for food preservation include dehydration, UV-C radiation, freeze-drying, and refrigeration. Chemical preservation and physical preservation techniques are sometimes combined.
In October 1912, when the 6th Chugoku Six Prefectures United Livestock Breeders' Show was held in Himeji City, Hyōgo Prefecture, two crossbred bulls won first prize as "Improved Japanese Breed" (改良和種, kairyō washu) and the term "Improved Japanese Breed" came into use thereafter. Thereafter, organized breeding efforts to increase the number of superior Wagyu cattle began. According to a survey conducted in 1914, there were 61 different breeds of Wagyu in Japan at that time, including Tajima cattle, Iwaizumi cattle, Mishima cattle, Aso cattle, and others. However, these were not actual breeds, but only names of regional classifications. In the case of Hyōgo Prefecture, the leading producer of Wagyu cattle (Kobe cattle and Tajima cattle) at that time, the number of stud bulls owned by breed as of 1914 was as follows.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.